VistaGen Therapeutics, Inc. (VTGN)
Largest Insider Buys in Sector
VTGN Stock Price History Chart
VTGN Stock Performance
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder …
Insider Activity of VistaGen Therapeutics, Inc.
Over the last 12 months, insiders at VistaGen Therapeutics, Inc. have bought $0 and sold $0 worth of VistaGen Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at VistaGen Therapeutics, Inc. have bought $4.54M and sold $100,275 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 775,756 shares for transaction amount of $17.96M was made by COMMODORE CAPITAL LP (10 percent owner) on 2023‑08‑07.
List of Insider Buy and Sell Transactions, VistaGen Therapeutics, Inc.
| 2023-08-07 | 10 percent owner | 775,756 22.7138% | $23.15 | $17.96M | -65.44% | |||
| 2022-08-18 | 100,000 0.0226% | $0.18 | $17,870 | -36.36% | ||||
| 2022-08-17 | CHIEF EXECUTIVE OFFICER | 600,000 0.1305% | $0.17 | $103,200 | -26.32% | |||
| 2022-08-17 | CHIEF LEGAL OFFICER | 300,000 0.0644% | $0.17 | $50,910 | -26.32% | |||
| 2022-07-12 | Sale | 10 percent owner | 60,000 0.0675% | $0.89 | $53,400 | -83.91% | ||
| 2022-07-12 | Sale | 60,000 0.0675% | $0.89 | $53,400 | -83.91% | |||
| 2021-09-07 | Sale | VP, CFO AND SECRETARY | 30,000 0.1186% | $3.13 | $93,750 | -55.73% | ||
| 2021-08-17 | PRES./CHIEF SCIENTIFIC OFFICER | 3,750 0.0129% | $2.73 | $10,238 | -44.65% | |||
| 2020-08-21 | director | 30,000 0.0262% | $0.69 | $20,700 | +208.70% | |||
| 2019-11-20 | PRES./CHIEF SCIENTIFIC OFFICER | 15,000 0.0064% | $0.34 | $5,100 | +88.24% | |||
| 2019-03-14 | director | 7,920 0.0128% | $1.27 | $10,086 | -42.19% | |||
| 2019-03-13 | director | 12,080 0.0192% | $1.26 | $15,201 | -41.27% | |||
| 2017-05-31 | director | 100,000 0.2529% | $2.00 | $200,000 | -33.86% | |||
| 2011-05-09 | Sale | PRESIDENT | 4.98M – | $0 | $0 | +59054.93% |
Insider Historical Profitability
| COMMODORE CAPITAL LP | 10 percent owner | 1575000 5.6566% | $2.50 | 1 | 0 | <0.0001% |
| Singh Shawn | CHIEF EXECUTIVE OFFICER | 626234 2.2491% | $2.50 | 1 | 0 | |
| Adler Reid G. | CHIEF LEGAL OFFICER | 334629 1.2018% | $2.50 | 1 | 0 | |
| GIN JERRY B | 100000 0.3592% | $2.50 | 2 | 0 | <0.0001% | |
| SAXE JON S | director | 50000 0.1796% | $2.50 | 3 | 0 | +208.7% |